Cognitive Enhancement in Bipolar Disorder

Phase 4 Completed 50 enrolled Northwell Health Stanley Medical Research Institute · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to examine whether the medication pramipexole (Mirapex) may be able to improve cognitive problems (i.e. difficulties with thinking, memory, and concentration) that may be associated with bipolar disorder.

Timeline

Start: 2005-10
Primary completion: 2011-04
Completion: 2011-04

Outcome

Missed primary endpoint

paper Primary cognitive analyses indicated no compelling cognitive benefit of pramipexole versus placebo; PMID 22152405 ↗

Publications

Results Burdick KE, Braga RJ, Nnadi CU, Shaya Y, Stearns WH, Malhotra AK. Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction. J Clin Psychiatry. 2012 Jan;73(1):103-12. doi: 10.4088/JCP.11m07299. Epub 2011 Nov 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pramipexole	Unknown	0.75 mg	Oral